Who we are
We are an international team committed and passionate about research, development, and innovation. We work to improve the health and quality of life of our patients.
Our Goal
To provide physicians with state-of-the-art precision diagnostic technology to avoid unnecessary surgeries in patients with indeterminate thyroid nodules. Through genomics and artificial intelligence, our technology provides safe and accurate information that enhances patient outcomes and quality of life. Our platform and results offer a unique opportunity to develop cutting-edge tests that address significant clinical questions and assist in key treatment decisions for patients.
Mission
To provide the best diagnostic certainty to personalize cancer treatment while helping to reduce costs and avoid unnecessary treatments that may harm people’s health. This way, physicians and patients can make best decisions based on state-of-the-art diagnostic tests.
Hernán González, Head and Neck Surgical Oncologist, MD, PhD.
Dr. Hernán González, a Head and Neck Surgical Oncologist from the Catholic University of Chile, noticed that many of his patients were undergoing unnecessary thyroidectomy for indeterminate nodules. As a scientist, he asked how can we identify patients who do not require surgery, considering that there are over 1.2 million new indeterminate cases worldwide each year.
The initial development of ThyroidPrint took place at the School of Medicine of the Catholic University of Chile and was supported by the Biomedicine Technological Consortium (BMRC). Once the prototype was ready and patented, Dr. González founded GeneproDX, the first Med-Tech spin-off of the UC.
Currently, GeneproDX offers ThyroidPrint® in 9 countries and continues to grow, avoiding hundreds unnecessary thyroid surgeries.
